With the increasing drug development for novel therapeutics, many pharmaceutical and biotech companies are seeking clinical manufacturing partners to help meet the demand for complex fill-and-finish solutions.

Also, while early drug development stages are challenging, Vetter, a globally leading contract development and manufacturing organization (CDMO), is committed to addressing this challenge by offering comprehensive expert manufacturing services for clinical trials and supporting its customer products' path to commercialization.

A testament to this commitment is evidenced by the success of its Skokie facility in Illinois, U.S., which has already contributed to bringing five new customer products to market since it began full operations in 2011, with another four expected to launch soon.

Since the site's opening, more than 240 customer audits have been successfully completed, and the facility has performed over 45 media fills without failure.

Vetter Development Service currently runs more than 80 projects in phases 1 and 2 clinical development.

In the past, the facility executed over 30 transfers from its early clinical projects to Germany for further late-stage development.

"Our clinical manufacturing sites are an essential part of Vetter's commercial business pipeline," said Dr. Claus Feussner, Senior Vice President of Vetter Development Service. "The Skokie site has demonstrated an impressive track record of success since its opening twelve years ago."

In 2022, the site acquired more than 10 new customers and their promising molecules, Feussner added.

Carsten Press, Senior Vice President of Vetter Key Account Management, Supply Chain Management and Marketing, also stressed that overall, the company's ongoing investments in clinical filling capabilities are proof of its consistent strategic approach to keeping abreast of the market and its focus on the important drug development needs of its customers.

Aside from Vetter's U.S. site, the company's newest clinical manufacturing site in Rankweil, Austria, has increased the company's capacity in the important field of process development as well as clinical manufacturing of phase 1 and 2 injectables for customers.

Purchased by Vetter in 2020, the facility received its manufacturing authorization at the end of 2021 and successfully completed its first customer fills beginning of 2022.

Vetter Development Services in Austria acts as a European counterpart to Skokie, helping to expand the CDMO's international presence and increase capacity.

Since its opening, the site's performance has proven exceptional, with fourteen projects already won and more in the pipeline.